Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Bladder cancer patients who start psychiatric meds post-surgery don't fare as well. A large retrospective study found that bladder cancer patients who began antidepressants and/or anxiolytics after radical cystectomy had significantly shorter overall survival — with anxiolytic use showing the starkest gap. Researchers suggest these medications may signal deeper psychological distress and survivorship vulnerability rather than directly causing harm.
A new study published in Psychooncology raises an important flag for oncology and psychiatry teams alike: bladder cancer patients who start antidepressants or anxiolytics after radical cystectomy (RC) — the surgical removal of the bladder — live significantly shorter lives than those who don't. The retrospective study drew on nearly 10,000 patients from the TriNetX US Collaborative Network, using propensity score matching to control for confounding factors.
The findings were especially stark for anxiolytic users, who had a median survival of just 113 days compared to 434 days in matched controls. Antidepressant-only users fared somewhat better but still showed a meaningful gap (140 vs. 325 days). Researchers are careful to note that the medications themselves may not be the culprit — rather, their use likely reflects underlying psychological burden and poorer overall health status.
Why it matters: For clinicians managing bladder cancer survivors, postoperative psychiatric medication use may serve as a practical, real-world red flag for patients at high survivorship risk — prompting earlier, more intensive supportive care interventions.
